Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Mike Ross - aVenture Research

Mike Ross

AddedMar 31, 2024

UpdatedOct 12, 2026

Mike Ross

Mike Ross

Board Member, Deciphera Pharmaceuticals

Mike Ross's Career

Deciphera Pharmaceuticals

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

$3.4BWaltham, MA, US

Board Member· Board

CyThera

Seed$2MSan Diego, CA, US

Board Member· Board

NKT Therapeutics

Series A$12MWaltham, MA, US

Board Member· Board

Link Medicine

Public$64.8MCambridge, MA, US

Board Member· Board

Adimab

Public$45.5MLebanon, NH, US

Board Member· Board

Archemix

$101.8MCambridge, MA, US

Board Member· Board

People Similar to Mike Ross

Fran HellerFounder & CEO · Good2Go

Errik AndersonBoard Member · Adimab

Leadership at Deciphera Pharmaceuticals

Michael D. TaylorCo-Founder

Ron SquarerBoard Member

Patricia AllenBoard Member

Susan KelleyBoard Member

James A. BristolBoard Member

Edward J. BenzBoard Member

Similar to Deciphera Pharmaceuticals

Karyopharm TherapeuticsNewton, MA, USPharmaceuticalsest. 2008Karyopharm TherapeuticsNewton, MA, US · est. 2008

US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.

Public · $546.7M385

Leadership at Archemix

Jean-François FormelaFounder

John MaraganoreBoard Member

Bob SteinBoard Member

Similar to Archemix

Guardian TherapeuticsLexington, MA, USTherapeuticsest. 2017Guardian TherapeuticsLexington, MA, US · est. 2017

Guardian Therapeutics, pioneering the limitless potential of aptamer therapeutics.

Series B · $30M75

Arch TherapeuticsFramingham, MA, USMedical Devicesest. 2009Arch TherapeuticsFramingham, MA, US · est. 2009

Arch Therapeutics: Innovating therapeutic solutions with peptide polymers to control bleeding.

Public · $27M7

HDL TherapeuticsVero Beach, FL, USCardiovascular, Therapeuticsest. 2009HDL TherapeuticsVero Beach, FL, US · est. 2009

HDL Therapeutics: FDA-approved biotech firm specializing in cardiovascular disease treatment.

Public · $10.8M6

Arete TherapeuticsHayward, CA, USDrug Developmentest. 2003Arete TherapeuticsHayward, CA, US · est. 2003

Arete Therapeutics Inc., a US biotech firm, innovates novel drugs for diabetes, hypertension, and inflammation.

Public · $51.7M30

Similar to CyThera

ViaCyteSan Diego, CA, USCell Therapiesest. 1999ViaCyteSan Diego, CA, US · est. 1999

ViaCyte: A San Diego-based regenerative medicine firm innovating cell therapies for diabetes.

Public · $235.5M175

Cellebration Life SciencesSan Diego, CA, USStem Cell Therapiesest. 2020Cellebration Life SciencesSan Diego, CA, US · est. 2020

Celebration: A pre-clinical R&D firm specializing in targeted stem-cell therapies for degenerative conditions.

Cyclo TherapeuticsGainesville, FL, USBiotech, Treatmentsest. 1990Cyclo TherapeuticsGainesville, FL, US · est. 1990

Cyclo Therapeutics: A US-based clinical-stage biotech firm developing treatments for unmet medical needs.

Public · $16.8M9

SpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Leadership at NKT Therapeutics

Mark TepperFounder

Robert MashalBoard Member

Dr Samuel Wu "Sam"Board Member

Similar to NKT Therapeutics

Nektar TherapeuticsSan Francisco, CA, USTherapeuticsest. 1990Nektar TherapeuticsSan Francisco, CA, US · est. 1990

Nektar Therapeutics, an American healthcare company, innovates polymer-based therapeutics.

Public · $1.2B216

NativisSeattle, WA, USTherapeuticsest. 2002NativisSeattle, WA, US · est. 2002

Nativis, a Seattle-based biotech firm, specializes in developing therapeutic modalities for serious diseases.

Series A · $21.1M30

Nerx BiosciencesIndianapolis, IN, USCancer Therapeuticsest. 2009Nerx BiosciencesIndianapolis, IN, US · est. 2009

US-based NĒRx BioSciences Inc, founded in 2009, specializes in discovering and developing targeted cancer therapeutics.

Seed · $500k11

Nuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series B · $48M75

Leadership at Link Medicine

John DeeBoard Member

Peter LansburyFounder

Dr Edward M ScolnickBoard Member

Similar to Link Medicine

Denali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427

Lysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5

EnterinPhiladelphia, PA, USBiomedical Products, Therapiesest. 2016EnterinPhiladelphia, PA, US · est. 2016

Enterin, Inc.: Global provider of innovative biomedical products and therapies for neurodegenerative diseases.

Series C · $81.6M26

Amylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262

Recent news

Adimab Collaborator GSK Receives Additional Marketing Approval for DepemokimabPRNewswire · 2026

Adimab Records Another Year of Double-Digit Clinical Program GrowthPRNewswire · 2026

Adimab Reports Strong Partnering Year for 2025PRNewswire · 2026

Leadership at Adimab

K. Dane WittrupChairman of Scientific Advisory Board

Bill MarisBoard Member

Tillman GerngrossBoard Member

Similar to Adimab

OmniAbEmeryville, CA, USAntibody Discoveryest. 2021OmniAbEmeryville, CA, US · est. 2021

OmniAb: Your pharmaceutical partner in discovering next-generation therapeutics through diverse antibody repertoires.

Public · $70M175

G1 TherapeuticsTriangle (historical), NC, USCancer Therapiesest. 2008

G1 TherapeuticsTriangle (historical), NC, US · est. 2008

US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.

Public · $697.4M170

Blueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641

VerastemNeedham, MA, USCancer Treatmentsest. 2010VerastemNeedham, MA, US · est. 2010

US-based Verastem, Inc. develops and commercializes cancer and tumor treatments, serving healthcare professionals.

Public · $280M100

Board Member

Terry McguireBoard Member

Philip ChaseBoard Member

Alloy TherapeuticsWaltham, MA, USAntibody Discovery, Biotech Platformsest. 2017

Alloy TherapeuticsWaltham, MA, US · est. 2017

Alloy Therapeutics: Democratizing drug discovery with innovative biotech platforms since 2017.

Series E · $168.3M134

InfinimmuneAlameda, CA, USAntibody Drugsest. 2022InfinimmuneAlameda, CA, US · est. 2022

Infinimmune is an Alameda, California biotechnology company discovering antibody therapeutics from sequenced human immune repertoires.

Series A · $87M7

ProteineaNewton, MA, USAntibody Medicinesest. 2020ProteineaNewton, MA, US · est. 2020

Proteinea: An Egypt/US-based biotech startup revolutionizing bio-manufacturing with insect-based platforms.

Seed · $2.8M58